Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783432 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 862
- Enrollment target
NCT00783432 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 862 participants.
The verdict
NCT00783432, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 862 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)
Interventions
- DRUG Astepro Nasal Spray (0.1% azelastine hydrochloride)
- DRUG Astelin Nasal Spray (0.1% azelastine hydrochloride)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 862 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00783432
The ClinicalTrials.gov registry entry for NCT00783432 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 862 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meda Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Astepro Nasal Spray (0.1% azelastine hydrochloride) is the first listed.
NCT00783432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00783432 about?
NCT00783432 is a clinical study titled "Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis". The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)
What is the current status of trial NCT00783432?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 862 participants. The study started on 2006-07. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00783432?
The interventions under investigation include: Astepro Nasal Spray (0.1% azelastine hydrochloride) (DRUG), Astelin Nasal Spray (0.1% azelastine hydrochloride) (DRUG).
Who is sponsoring clinical trial NCT00783432?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.